CXCL13 expression has been correlated with TLS rates in esophageal squamous cell carcinoma, non-small-cell lung carcinoma, stomach adenocarcinoma, and malignant mesothelioma, and it has been suggested as a predictive marker for immune checkpoint inhibitor-responsive bladder cancer (Groeneveld et al., 2021). Here, CXCL13 is linked to esophageal squamous cell carcinoma.